Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis
- Daniel Picard 1, Suzanne Miller , Cynthia E Hawkins , Eric Bouffet , Hazel A Rogers , Tiffany S Y Chan , Seung-Ki Kim , Young-Shin Ra , Jason Fangusaro , Andrey Korshunov , Helen Toledano , Hideo Nakamura , James T Hayden , Jennifer Chan , Lucie Lafay-Cousin , Pingzhao Hu , Xing Fan , Karin M Muraszko , Scott L Pomeroy , Ching C Lau , Ho-Keung Ng , Chris Jones , Timothy Van Meter , Steven C Clifford , Charles Eberhart , Amar Gajjar , Stefan M Pfister , Richard G Grundy , Annie Huang
- 1Division of Hematology-Oncology, Arthur and Sonia Labatt Brain Tumour Research Centre, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
- 0Division of Hematology-Oncology, Arthur and Sonia Labatt Brain Tumour Research Centre, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Molecular markers LIN28 and OLIG2 identify three subgroups of aggressive childhood brain tumors (CNS PNETs). These markers aid in diagnosis and prognosis, guiding future clinical trials for better patient outcomes.
Area Of Science
- Neuro-oncology
- Pediatric oncology
- Molecular pathology
Background
- Childhood Central Nervous System Primitive Neuro-ectodermal Brain Tumours (CNS PNETs) are aggressive and poorly understood.
- Current treatment strategies lack molecular guidance.
- Identifying molecular markers is crucial for improving clinical management.
Purpose Of The Study
- To identify molecular markers for classifying childhood CNS PNETs.
- To enhance the clinical management of this rare and aggressive brain tumour.
- To discover diagnostic and prognostic indicators for CNS PNETs.
Main Methods
- Analysis of 142 primary hemispheric CNS PNET samples from a global cohort.
- Transcriptional and copy number profiling of tumour subsets.
- Clustering, gene, pathway enrichment, immunohistochemical, and gene-expression analyses were employed.
Main Results
- Three distinct molecular subgroups of CNS PNETs were identified based on gene-expression signatures (primitive neural, oligoneural, mesenchymal).
- LIN28 and OLIG2 expression levels differentiated these subgroups.
- Group 1 (primitive neural) showed poorer survival and a female predominance, while Group 3 (mesenchymal) had a higher incidence of metastases.
Conclusions
- LIN28 and OLIG2 serve as promising molecular markers for CNS PNET diagnosis and prognosis.
- These markers warrant further investigation in prospective clinical trials.
- Molecular subtyping can significantly impact the understanding and treatment of childhood CNS PNETs.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.